Boston Therapeutics

October 2013

Leaders in Complex Carbohydrate Chemistry

Company Overview

Boston Therapeutics, Inc., (OTCQB: BTHE), "BTHE" or the "Company", is a clinical stage, pharmaceutical company that designs drugs utilizing Complex Carbohydrate Chemistry (CCC). These compounds address areas of high unmet medical need such as diabetes. The Company has two compounds, PAZ320 in Phase II/III clinical trials and IPOXYN in pre-clinical stage. BTHE has a unique chemistry approach to developing non-systemic safe and efficacious drug candidates that can be used alone or combined with existing therapies.

Highlights

- ✓ BTHE's lead product, PAZ320, represents a near term commercial opportunity in the large and growing $35B diabetes drug market.
- ✓ PAZ320 is enhanced due to its GRAS (Generally Regarded as Safe) classification, and 505(b)(2) accelerated development pathway for FDA approval.
- ✓ Potential to co-administer PAZ320 with Metformin, the most widely prescribed diabetes drug with 50M prescriptions written annually in the U.S., represents a compelling value creation opportunity.
- ✓ BTHE's founder, Dr. David Platt, is a world renowned scientist and developed or co-developed the core technologies of three public companies and his research in galectins is core for a fourth company.
- ✓ The Company recently raised $5.3M to enhance its drug development efforts.

Key Products

• **PAZ320** is a non-systemic, non-toxic, chewable tablet designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal tract to inhibit carbohydrate-hydrolyzing enzymes that release glucose from carbohydrates during digestion, thus reducing the availability of glucose for absorption into the bloodstream. Lower blood glucose is believed to slow the onset and progression of diabetes and its complications.



• **IPOXYN** is a carbohydrate-based intravenous solution that can potentially prevent necrosis, or cell death, and treat hypoxic conditions such as diabetic foot ulcers and other vascular complications of diabetes. BTHE is planning to introduce this product in clinical trials for hypoxic medical conditions. The Company also has developed OXYFEX, a veterinary analog to IPOXYN.

Milestones

Product	2013	2014	2015	2016
PAZ320	• Publish Phase II data • Initiate Phase II trial in France	• File IND • Initiate Phase III study	• Clinical studies report finalized	• New Drug Application (NDA)
IPOXYN	• Initiate pre-clinical experiments	• Short term toxicity studies Pre-IND meeting with FDA	• IND application	• First in human study indication

Development Strategy

- BTHE plans to accelerate development of its 2 lead products over the next 12-18 months by employing a FDA 505(b)(2) regulatory strategy for its drugs.
- 505(b)(2) is a faster way of getting drugs approved as the Company can use non Company data to support its own clinical studies.

Boston Therapeutics

August 2013

Development Status

Product	Description	Indication	Development Status: R&D	Preclin.	Phase 1	Phase 2	Phase 3
PAZ320	Chewable tablet that manages blood sugar	Type 2 Diabetes			→		
IPOXYN™	Injectible anti-necrosis drug	Lower-limb ischemia in diabetic patients			→		

Diabetes: A Growing Epidemic

- Over 33% of the U.S. population is diabetic or pre-diabetic
- If current trends continue, by 2050, 1 of 3 U.S. adults will have diabetes
- 26mm+ have diabetes in the U.S.; 8.3% of the population
  - 460% increase since 1980
- Type 2 diabetes is the 7th leading cause of death in the U.S.
- The American Diabetes Association estimates the total cost of diagnosed diabetes in 2012 to be $245 billion in the United States.
- The diabetes market contains many formulations, however, many have side effects that limit their usage and/or cause serious toxicity.

US Population with Diagnosed Diabetes



New US cases of diagnosed diabetes

Adults aged 18-79 years



Complications of Diabetes Drugs



www.bostonti.com

IPOXYN: Market Opportunity

IPOXYN is a carbohydrate-based intravenous solution that can potentially prevent necrosis, or cell death, and treat hypoxic conditions such as diabetic foot ulcers. Hypoxia is a condition in which cells lack sufficient oxygen supply to support metabolic function. IPOXYN contains oxygen rechargeable iron which picks up oxygen in the lungs, is 5,000 times smaller than a red blood cell and can reach hypoxic tissue more effectively. IPOXYN is stable at room temperature, has a five year shelf life and requires no blood type matching. The Company has also developed OXYFEX, a veterinary analog.

- Global shortage of 110 million units of transfusion-suitable blood.
- The global market opportunity for anti-hypoxia or anti-necrosis technology is $30 billion.
- Over 60% of non-traumatic lower-limb amputations were performed on people with diabetes.

Key Management

Team	Background
David Platt, Ph.D., Chairman and CEO	• Expert in complex carbohydrate chemistry and founder of three publicly traded companies • Founder, former CEO & Chairman of Pro-Pharmaceuticals, Inc. (OTC: PRWP / AMEX: PRW) and SafeScience, Inc. (Nasdaq: SAFC) • Led development of two drug candidates from concept through phase II clinical trials
Kenneth Tassey, President	• Co-founder and President of Boston Therapeutics, Inc. since November 2010 • CEO & President of Boston Therapeutics from 2009 until merger with Avanyx Therapeutics
Anthony Squeglia, Vice President of Strategic Planning & Investor Relations	• Former CFO for Galectin Therapeutics, Inc. (Nasdaq: GALT) and its predecessor company Pro-Pharmaceuticals, Inc. 2007 to 2012 • VP Investor Relations for PRWP, 2003 to 2007 • Senior management positions at Unisys, AT&T, Summa Four, ITT and Quentra Networks

Contact: Anthony Squeglia
VP of Strategic Planning & IR
anthony.squeglia@bostonti.com
(603) 935-9799; (603) 512.6593 (C)

Any statements in this fact sheet about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this fact sheet and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.